Pfizer Inc PFE

$28.40 +0.12 (0.42%)

Valuation

Market cap
161,186,784,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
PE ratio
9.12
Forward PE
9.35
Profit margin
12.42%
Debt to equity
0.74

Trading

Volume
17,924,809
Avg volume
35,305,168
Day's range
$28.28 – $28.50
Shares out
5,699,674,000
Stochastic %K
64%
Beta
0.32
Analysts
Sell
Price target
$29.45

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

JimCoolFalk Oct 12, 5:47 PM
$PFE seems a bit overbought
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:44 PM
$SLS $JNJ $PFE $MRK $BMY GPS Groundbreaking results which show a huge difference between GPS and BAT, potentially approaching transplant survival rates without the huge risks/recovery, means that expansion within AML is all but guaranteed, and expansion into other 20+ cancers that can achieve low disease burden will immediately be followed up on. In this scenario, letting a rival pharma company acquire SLS comes with pretty big risks, so a bidding war becomes increasingly likely. I would expect an acquisition to follow fairly quickly in this scenario, probably within a few days of results, because Sellas would be very happy to accept the best offer they receive, and whoever the bidder is would want full control over the BLA application and subsequent expansion of further trials ASAP. They would likely be willing to pay the sort of values that get thrown around here based on the expected returns, and Sellas would be very happy to accept an offer! ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:40 PM
$BMY $JNJ $MRK $PFE $SLS GPS Groundbreaking results which show a huge difference between GPS and BAT, potentially approaching transplant survival rates without the huge risks/recovery, means that expansion within AML is all but guaranteed, and expansion into other 20+ cancers that can achieve low disease burden will immediately be followed up on. In this scenario, letting a rival pharma company acquire SLS comes with pretty big risks, so a bidding war becomes increasingly likely. I would expect an acquisition to follow fairly quickly in this scenario, probably within a few days of results, because Sellas would be very happy to accept the best offer they receive, and whoever the bidder is would want full control over the BLA application and subsequent expansion of further trials ASAP. They would likely be willing to pay the sort of values that get thrown around here based on the expected returns, and Sellas would be very happy to accept an offer! ✌️🙏❤️‍🩹
0 replies
InjectiveX Oct 12, 5:34 PM
$PFE The next RMTG report could be important for understanding whether the company’s operating growth is outpacing its financing burden. Q2 revenue and operating income improved substantially year over year, yet interest expense contributed to a $2.91M net loss.
0 replies
SellasgpsCurativeBAT11 Oct 12, 5:32 PM
$SLS $JNJ $MRK $PFE $AZN Looking at 2 year PR history Tuesday is #1 PR day for Sellas Life Sciences. ✌️🙏❤️‍🩹
0 replies
GlassIsHalfEmpty Oct 12, 1:01 PM
$IBRX Yes I saw that and they also had former FDA comisioner Scott Gotlieb talking about sepsis. But i wasn’t paying attention since he’s a $PFE stick promoter and employee.
1 replies
Agent8 Oct 12, 9:05 AM
$PFE Ai changing everything: https://www.wsj.com/business/media/the-ai-change-that-let-pfizers-albert-bourla-sleep-better-51d371b2 LT
0 replies
truthseeeker Oct 12, 8:26 AM
$PFE Just a note of perspective. PFE was up nicely on friday and is slightly higher in premarket this am. The reason for the Friday surge was noted by several sources as a sympathy move due to the NY TIMES shtory that the NIH would be embarking on a push for Cancer Vaccines. So Moderna, Vaxcyte etc were the big gainers. They have products in stage trials for this category. But PFE has NO cancer vaccines in its pipeline. A reasonable perspective says this could be NEGATIVE for PFE as cancer vaccines if effective would out compete PFE more conventional products. Another reasoon to sell the PFE really.......
2 replies